News

Sequenom Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostic Test

Sequenom, Inc. (NASDAQ: SQNM), today announced an exclusive worldwide licensing agreement with Optherion, Inc.

Optherion Announces Issuance of Canadian Patents Covering Age-Related Macular Degeneration Diagnostics and Treatments

Issuance of Canadian Patents 2,363,503 and 2,407,715 Strengthens Intellectual Property Position of Optherion’s Novel Diagnostics for Age-Related Macular Degeneration

Optherion Announces Presentation at ARVO 2009 Annual Meeting

A Clinical Study to Identify a Population with Blood-Based Biomarkers for Age-Related Macular Degeneration (AMD)

Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations

Optherion, Inc. announced today that it has licensed from the University of Pittsburgh the worldwide rights to develop diagnostic products for AMD associated with specific variations in genes on Chromosome 10.

Optherion, Inc. Completes $37 Million Start Up Financing

Financing Will Advance Development of Diagnostics and Disease-Modifying Therapeutics for Dry and Wet Age-Related Macular Degeneration and Other Diseases Associated with Alternative Complement System

Optherion's Genetic Research in Dry AMD Featured in Forbes

Article Says “Breakthrough” May Offer Hope for Millions

Optherion, Inc. Selected as the Edwards Angell Palmer & Dodge Award Winner By the Connecticut Technology Council. Also Recognized as One of 100 Technology “Companies to Watch”